Teva Pharmaceutical Industries (NYSE:TEVA) Shares Gap Down – What’s Next?

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) gapped down prior to trading on Friday . The stock had previously closed at $16.75, but opened at $16.22. Teva Pharmaceutical Industries shares last traded at $16.56, with a volume of 634,057 shares traded.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on TEVA shares. Barclays increased their price target on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. JPMorgan Chase & Co. increased their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Finally, UBS Group increased their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $19.67.

Teva Pharmaceutical Industries Stock Down 1.9 %

The firm has a 50 day moving average price of $17.78 and a two-hundred day moving average price of $17.22. The firm has a market capitalization of $18.61 billion, a price-to-earnings ratio of -19.33, a price-to-earnings-growth ratio of 1.32 and a beta of 0.87. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Sequoia Financial Advisors LLC increased its holdings in Teva Pharmaceutical Industries by 0.7% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company’s stock valued at $2,025,000 after purchasing an additional 805 shares in the last quarter. Smithfield Trust Co grew its stake in shares of Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after buying an additional 980 shares in the last quarter. Signaturefd LLC raised its holdings in shares of Teva Pharmaceutical Industries by 16.9% during the 3rd quarter. Signaturefd LLC now owns 7,583 shares of the company’s stock valued at $137,000 after buying an additional 1,094 shares during the period. Bridgewater Associates LP lifted its position in Teva Pharmaceutical Industries by 5.2% during the 3rd quarter. Bridgewater Associates LP now owns 23,222 shares of the company’s stock worth $418,000 after acquiring an additional 1,144 shares in the last quarter. Finally, Oppenheimer & Co. Inc. boosted its holdings in Teva Pharmaceutical Industries by 9.6% in the 1st quarter. Oppenheimer & Co. Inc. now owns 13,522 shares of the company’s stock worth $191,000 after acquiring an additional 1,180 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.